Fortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024. In the quarter to June 2026, revenue fell 4.52%, EPS grew 96.6%, free cash flow grew 53.2% and total debt fell 10.3%, each against the same quarter a year earlier.
Follow FTRE
Fortrea Holdings Inc. (FTRE) EV/Sales
As of 16 October 2026, Fortrea Holdings Inc. (FTRE) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.0× (June 2023) to 1.8× (April 2024); the current reading is higher than 65% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (9.27%) |
| FY2024 | 1.0× | (37.93%) |
| FY2023 | 1.6× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | 43.52% |
| Mar 2026 | 0.7× | (26.67%) |
| Dec 2025 | 0.9× | 40.88% |
| Sep 2025 | 0.6× | 13.26% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| FTRE Fortrea Holdings Inc. | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| NVAX Novavax, Inc. compare | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| VCEL Vericel Corporation compare | 6.2× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 23.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)